Muscle Growth Research Market

IGF-1 DES

A truncated IGF-1 analog that remains a familiar name in performance and tissue-growth peptide discussions.

IGF-1Muscle GrowthGrowth FactorResearch Market

Also referenced as: IGF-1 DES(1-3)

Also appears in: Growth Hormone

Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Category
Muscle Growth

Primary lane: Muscle Growth. Also surfaces under Growth Hormone for browsing and discovery.

Aliases
1

IGF-1 DES(1-3)

Signal depth
Low

No FDA label signal · 0 trials · 6 PubMed results

Preclinical
Research evidence

Current evidence for IGF-1 DES is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

IGF-1 DES has no clinical trials that name it and 6 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
Established
Comparative Study Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis. Comparative Study IGF-I has a dual effect on insulin release from isolated, perifused adult rat islets of Langerhans. Journal Article The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins. Comparative Study The direct in vitro effect of insulin-like growth factors (IGFs) on normal bovine mammary cell proliferation and production of IGF binding proteins. Journal Article A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What IGF-1 DES is

IGF-1 DES is a truncated analog of insulin-like growth factor 1, typically discussed in performance and tissue-growth circles rather than mainstream medicine.

Why it matters

It is still one of the more recognizable growth-factor names missing from many peptide libraries, especially for users who know the difference between growth hormone secretagogues and direct growth-factor analogs.

Regulatory context

IGF-1 DES is not FDA approved as a mainstream therapeutic product. It fits best in the research-market category.

Practical reading note

Because IGF-1 language sounds medical and familiar, this is one of the easier compounds for people to overread. The research-market versions are not the same as a broadly established drug pathway.